

**REFERENCE RELATING TO THE ANTICIPATED ACQUISITION BY
ILLUMINA, INC OF PACIFIC BIOSCIENCES OF CALIFORNIA, INC.**

**Notice of extension of inquiry period under section 39(3) of the
Enterprise Act 2002¹**

1. On 27 June 2019, the Competition and Markets Authority (CMA), in exercise of its duty under section 33(1) of the Enterprise Act 2002 (the Act), referred the anticipated acquisition by Illumina, Inc ('Illumina') of Pacific Biosciences of California, Inc ('PacBio') (together 'the Parties') (the reference) to its Chair for the constitution of a Group of CMA Panel Members ('the Inquiry Group'). The period within which the report on this reference was to be prepared and published (the reference period) was due to expire on 11 December 2019.
2. On 24 October 2019, the Inquiry Group appointed to consider the reference published its Provisional Findings and a Notice of Possible Remedies.
3. The Inquiry Group considers that completion of its investigation and the publication of its final report will not be possible within the original reference period and has decided that the reference period should be extended by eight weeks under section 39(3) of the Act. The revised reference period will expire on 5 February 2020. However, the Inquiry Group aims to complete the inquiry as soon as possible and in advance of this date.
4. In taking this decision, the Inquiry Group had regard to the complexity of the subject matter and the need to allow sufficient time to take full account of representations received in response to the Notice of Possible Remedies and Provisional Findings in our final decision.

Stuart McIntosh
Inquiry Group Chair
26 November 2019

¹ Published pursuant to section 107(2)(c) of the Enterprise Act 2002